Core Insights - The report highlights significant changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - The companies with the largest increases in Hong Kong Stock Connect holdings include: - Hang Seng China Enterprises (02828) with an increase of 6.65%, bringing the total holding to 8.92% [2]. - Tracker Fund of Hong Kong (02800) with an increase of 2.53%, now at 4.89% [2]. - Southern Hang Seng Technology (03033) with an increase of 1.68%, totaling 60.17% [2]. - In the recent five trading days, the largest increases were seen in: - Derun Holdings (01709) with a 7.99% increase, now at 26.35% [3]. - Changfei Optical Fiber (06869) with a 5.86% increase, now at 55.28% [3]. - Chifeng Jilong Gold Mining (06693) with a 3.43% increase, now at 41.14% [3]. Group 2: Decreased Holdings - The companies with the largest decreases in Hong Kong Stock Connect holdings include: - Nanjing Panda Electronics (00553) with a decrease of 1.40%, now at 42.68% [2]. - Dongfang Electric (01072) with a decrease of 1.07%, now at 39.13% [2]. - Dongyang Sunshine Pharmaceutical (06887) with a decrease of 0.99%, now at 49.32% [2]. - In the recent five trading days, the largest decreases were noted in: - Kailai Pharmaceutical (06821) with a decrease of 5.31%, now at 46.07% [3]. - Dongyang Sunshine Pharmaceutical (06887) with a decrease of 3.72%, now at 49.32% [3]. - Ganfeng Lithium (01772) with a decrease of 2.58%, now at 33.34% [3]. Group 3: Long-term Trends - Over the past 20 days, the largest increases in holdings were observed in: - Changfei Optical Fiber (06869) with a 25.54% increase, now at 55.28% [4]. - Dongfang Electric (01072) with an 11.80% increase, now at 39.13% [4]. - The largest decreases over the same period were in: - Marco Digital Technology (01942) with a decrease of 9.72%, now at 42.63% [4]. - Longpan Technology (02465) with a decrease of 6.79%, now at 44.90% [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第13.10B條作出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女士 、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董事孫 雪嬌博士、侯欣一博士及李家聰先生組成。 证券代码：002821 证券简称：凯莱英 公告编号：2025-053 凯莱英医药集团（天津）股份有限公司 关于签署募集资金三方监管协议的公告 凱萊英醫藥集團（天津）股份有限公司 Hao Hong博士 董事長、執行董事兼首席執行官 ...

凯莱英医药集团（天津）股份有限公司 关于签署募集资金三方监管协议的公告 本公司及全体董事会成员保证公告内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准凯莱英医药集团（天津）股份有限公 司非公开发行股票的批复》（证监许可[2020] 1912号）的核准，凯莱英医药集团 （天津）股份有限公司（以下简称"公司"）非公开发行人民币普通股股票（A股） 10,178,731.00股，每股面值1元，发行价格为227.00元/股，募集资金总额人民 币2,310,571,937.00元，扣除与发行有关的费用人民币35,611,280.94元，公司 实际募集资金净额为人民币2,274,960,656.06元。截至2020年9月23日止，上述 募集资金已全部到账，已经容诚会计师事务所（特殊普通合伙）审验 ，出具了 容诚验字[2020]100Z0073号验资报告。 证券代码：002821 证券简称：凯莱英 公告编号：2025-053 具体募集资金专项账户的开立情况如下： | 序号 | 账户名称 | 开户行名称 | 银行账号 | 募投项目 | | --- | -- ...

Core Insights - The report highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2][3][4][5]. Group 1: Increased Holdings - Beijing North Star Industrial Co., Ltd. (00588) saw the largest increase in holdings, up by 1.58%, with a current holding ratio of 43.40% [1] - Fubo Group (03738) and Weimob Inc. (02013) also experienced notable increases of 1.37% and 0.99%, respectively, with holding ratios of 35.89% and 30.88% [1] - Over the last five trading days, Delin Holdings (01709) had the highest increase at 7.63%, bringing its holding ratio to 25.85% [3] - Changfei Optical Fiber Cable (06869) and Haotian International Construction Investment (01341) also saw significant increases of 6.30% and 5.11%, with holding ratios of 53.79% and 57.60% [3] Group 2: Decreased Holdings - Ganfeng Lithium Co., Ltd. (01772) experienced the largest decrease in holdings, down by 3.11%, with a current holding ratio of 33.86% [2] - Longpan Technology (02465) and Southern Hengsheng Technology (03033) also saw decreases of 2.61% and 1.48%, with holding ratios of 43.90% and 58.49% [2] - Over the last five trading days, Yisou Technology (02550) had the most significant decrease at 8.24%, with a holding ratio of 48.23% [3] - Longpan Technology (02465) and Kailai Ying (06821) also faced reductions of 4.48% and 4.45%, with holding ratios of 43.90% and 46.47% [3] Group 3: 20-Day Changes - Over the past 20 days, Changfei Optical Fiber Cable (06869) had the highest increase at 25.23%, with a holding ratio of 53.79% [4] - Other notable increases included Dongfang Electric (01072) and China Energy Construction (03996), with increases of 12.87% and 11.27%, holding ratios of 40.20% and 20.35% respectively [4] - Conversely, Marco Digital Technology (01942) saw the largest decrease at 9.71%, with a holding ratio of 42.65% [5] - Longpan Technology (02465) and Chongqing Steel (01053) also experienced significant decreases of 6.82% and 6.48%, with holding ratios of 43.90% and 33.24% [5]

Group 1 - The Hong Kong stock market showed strong performance on August 13, with the Hang Seng Index rising by 1.88% and the Hang Seng Tech Index increasing by 2.35%, particularly driven by the healthcare sector [1] - The Hong Kong Innovative Drug 50 ETF (513780) closed up by 3.38% with a turnover rate exceeding 18% and a transaction volume of over 400 million yuan, indicating strong investor interest [1] - Notably, the Hong Kong Innovative Drug 50 ETF (513780) experienced a net inflow of 1.07 billion yuan over the past 15 trading days, and it has gained over 92% year-to-date as of August 12 [1] Group 2 - The National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance directory and commercial insurance innovative drug directory, with 534 drugs passing the basic medical insurance directory review and 121 drugs passing the commercial insurance innovative drug directory review [2] - High-priced innovative drugs, including CAR-T therapies, are seeking inclusion in the commercial insurance innovative drug directory, indicating a push for diversified payment methods for innovative drugs [2] - Analysts suggest that the rise of innovative drugs is sustainable, recommending attention to companies with rich pipeline layouts, high-potential single innovative drugs, and leading technology platforms in the sector [2]

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Longpan Technology (02465) saw the largest increase in holdings, up by 3.25% to a total of 46.51% [1] - Derin Holdings (01709) experienced a 2.51% increase, bringing its total to 25.62% [1] - HuTongDa Network (09878) increased by 2.39%, reaching 29.81% [1] - In the last five trading days, Changfei Optical Fiber Cable (06869) had the highest increase at 7.59%, with a total holding of 53.37% [1] - Derin Holdings (01709) also saw a significant increase of 7.29% [1] Group 2: Decreased Holdings - Kailaiying (06821) had the largest decrease in holdings, down by 3.38% to 47.22% [1] - Dongyang Sunshine Pharmaceutical (06887) decreased by 1.55%, now at 51.49% [1] - Fubo Group (03738) saw a reduction of 1.26%, with a current holding of 34.52% [1] - Over the last five trading days, Hengsheng China Enterprises (02828) experienced the most significant drop at -16.55%, now at 2.47% [1] Group 3: Long-term Trends - Over the past 20 days, Changfei Optical Fiber Cable (06869) had a substantial increase of 24.95%, reaching 53.37% [1] - Derin Holdings (01709) increased by 10.51% over the same period, now at 25.62% [1] - The data indicates a trend of fluctuating investor interest in various sectors, with some companies gaining traction while others are losing it [1][2].

格隆汇8月13日丨根据联交所最新权益披露资料显示，2025年8月8日，凯莱英(06821.HK)获Norges Bank在场内以每股均价90.212港元增持47.28万股，涉资约 4265.22万港元。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關法 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 股份數目 | | | (語參閱十犹*詩 | 有投票權股 期 (日 / 月 / | | | | | | | | | 份百分比 年) | | | | | | | | | ( 0/2 | | CS20250811E00523 | Norges Bank | 1101(L) | | 472,800(L | HKD 90.2120 | 3.179.200(L) | 11.54(L)08/08/2025 | 增持后，Norges Bank最新持股数目为317.92万股，持股比例由9.82%上升至11.54%。 | 股份代號: | 0 ...

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a recent decline in net value but positive returns over various time frames [1] - As of August 12, 2025, the latest net value of the fund is 1.9165 yuan, reflecting a decrease of 0.56%. The fund's one-month return is 7.20%, six-month return is 23.93%, and year-to-date return is 22.17% [1] - The fund's top ten stock holdings account for a total of 54.73%, with notable positions in WuXi AppTec (10.39%), Hengrui Medicine (9.69%), and Kanglong Chemical (5.05%) among others [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and as of June 30, 2025, it has a total scale of 15.638 billion yuan [1] - The fund is managed by two key individuals: Ms. Ge Lan, who has been the fund manager since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

香港联交所最新数据显示，8月8日，Norges Bank增持凯莱英（002821）(06821)47.28万股，每股作价 90.212港元，总金额约为4265.22万港元。增持后最新持股数目为317.92万股，持股比例为11.54%。 ...

智通财经APP获悉，香港联交所最新数据显示，8月8日，Norges Bank增持凯莱英(06821)47.28万股，每 股作价90.212港元，总金额约为4265.22万港元。增持后最新持股数目为317.92万股，持股比例为 11.54%。 ...